Biomonitoring Equivalents for triclosan

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 1, 2010, Pages 10-17

  Krishnan, Kannan ^a   Gagné, Michelle ^a   Nong, Andy ^b   Aylward, Lesa L ^c   Hays, Sean M ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HEALTH CANADA   (Canada)

^c LLP   (United States)

Author keywords

Biomonitoring Equivalents; Pharmacokinetics; Risk assessment; Triclosan

Indexed keywords

BIOLOGICAL MARKER; CREATININE; TRICLOSAN;

ARTICLE; BIOLOGICAL MONITORING; BLOOD LEVEL; CHRONIC TOXICITY; HEALTH HAZARD; HUMAN; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; STANDARDIZATION; TOXICOKINETICS; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS, LOCAL; BIOLOGICAL MARKERS; CHILD; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; ENVIRONMENTAL POLLUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; TRICLOSAN; YOUNG ADULT;

ANIMALIA;

EID: 77955922109     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.06.004     Document Type: Article

References (49)

1. Adolfsson-Erici M., Pettersson M., Parkkonen J., Sturve J. Triclosan, a commonly used bactericide found in human milk and in the aquatic environment in Sweden. Chemosphere 2002, 46:1485-1489.
2. Allmyr M., Harden F., Toms L.M., Mueller J.F., McLachlan M.S., Adolfsson-Erici M., Sandborgh-Englund G. The influence of age and gender on triclosan concentrations in Australian human blood serum. Sci. Total Environ. 2008, 393(1):162-167.
3. Allmyr M., Panagiotidis G., Sparve E., Diczfalusy U., Sandborgh-Englund G. Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. Basic Clin. Phamacol. 2009, 105:339-344.
4. Aylward L.L., Hays S.M. Biomonitoring equivalents (BE) dossier for 2, 4-dichlorophenoxyacetic acid (2,4D) (CAS No. 94-75-7). Reg. Toxicol. Pharmacol. 2008, 51:S37-S48.
5. Bagley D.M., Lin Y.J. Clinical evidence for the lack of triclosan accumulation from daily use in dentifrices. Am. J. Dent. 2000, 13:148-152.
6. Barr D.B., Wilder L.C., Caudill S.P., Gonzalez A.J., Needham L.L., Pirkle J.L. Urinary creatinine concentrations in the US population, implications for urinary biologic monitoring measurements. Environ. Health Perspect. 2005, 113:192-200.
7. Bhargava H.N., Leonard P.A. Triclosan, applications and safety. Am. J. Infect Control 1996, 24:209-218.
8. Calafat A.M., Ye X., Wong L.Y., Reidy J.A., Needham L.L. Urinary concentrations of triclosan in the US population 2003-2004. Environ. Health Perspect 2008, 116:303-307.
9. Ciba-Geigy Corporation, 1986. FAT 80'023: 2-Year Oral Administration to Rats. Unpublished Report No. MIN 83305, Pharmaceuticals Division, Ciba-Geigy Corporation, NJ, USA (as cited in NICNAS (2009)).
10. Ciba-Geigy Limited, 1976. Pharmacokinetic and Metabolic Studies in Man Following Oral Administration of a 14C-Labelled Preparation. Unpublished Report No: B 6/1976. Ciba-Geigy Limited, Basel, Switzerland (as cited in NICNAS (2009)).
11. Ciba-Geigy Limited, 1977. Comparison of Pharmacokinetic and Metabolic Parameters of Triclosan and HCP in the Mouse, Rat, Beagle Dog and Baboon, Part A: Survey of Findings, Part B: Detailed Account of the Study. Unpublished Report No: B 1/1977. Ciba-Geigy Limited, Basel, Switzerland (as cited in NICNAS (2009)).
12. Ciba-Geigy Limited, 1990. Report on Partition Coefficient - by OECD TG 107. Unpublished Test Report: Anal. Test. No. FC-90/1T. Ciba-Geigy Limited, Basel, Switzerland.
13. Crofton K.M., Paul K.B., DeVito M.J., Hedge J.M. Short-term in vivo exposure to the water contaminant triclosan: evidence for disruption of thyroxine. Environ. Toxicol. Pharmacol. 2007, 24:194-197.
14. Dayan A.D. Risk assessment of triclosan [Irgasan] in human breast milk. Food Chem. Toxicol. 2007, 45:125-129.
15. DeSalva S.J., Kong B.M., Lin Y.J. Triclosan: a safety profile. Am. J. Dent. 1989, 2:185-196.
16. Drake, J.C., Buxtorf, A., 1976. 1 Year Oral Toxicity Study in Baboons with Compound FAT 80 023/A. Geigy Pharmaceuticals, Toxicology Department, MRID # 133230.
17. Engelhaupt, E., 2007. More Triclosan Trouble. Environmental Science and Technology. American Chemical Society, p. 2072 (March 1st, 2010) http://pubs.acs.org/doi/pdfplus/10.1021/es072500z.
18. European Commission, 2009. Scientific Committee on Consumer Products (SCCP) Opinion on Triclosan COLIPA No. P32 (May 21th, 2009) http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_166.pdf.
19. Garde A.H., Hansen A.M., Kristiansen J., Knudsen L.E. Comparison of uncertainties related to standardization of urine samples with volume and creatinine concentration. Ann. Occup. Hyg. 2004, 48:171-179.
20. Hanioka N., Omae E., Nishimura T., Jinno H., Onodera S., Yoda R., et al. Interaction of 2,4,4'-trichloro-2'-hydroxydiphenyl ether with microsomal cytochrome P450-dependent monooxygenases in rat liver. Chemosphere 1996, 33:265-276.
21. Hays S.M., Aylward L.L. Biomonitoring equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Reg. Toxicol. Pharmacol. 2008, 51:S57-S67.
22. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk C., DiZio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W. Guidelines for the derivation of biomonitoring equivalents: report from the biomonitoring equivalents expert workshop. Regul. Toxicol. Pharmacol. 2008, 51:S4-S15.
23. Hays S.M., Becker R.A., Leung H.W., Aylward L.L., Pyatt D.W. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective. Regul. Toxicol. Pharmacol. 2007, 47:96-109.
24. Heath R.J., Rubin J.R., Holland D.R., Zhang E., Snow M.E., Rock C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 1999, 274:11110-11114.
25. Hovander L., Malmberg T., Athanasiadou M., Athanassiadis I., Rahm S., Bergman A., Wehler E.K. Identification of hydroxylated PCB metabolites and other phenolic halogenated pollutants in human blood plasma. Arch. Environ. Contam. Toxicol. 2002, 42:105-117.
26. Jacobs M.N., Nolan G.T., Hood S.R. Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol. Appl. Pharmacol. 2005, 209:123-133.
27. LaKind J.S., Aylward L.L., Brunk C., DiZio S., Dourson M., Goldstein D.A., Kilpatrick M.E., Krewski D., Bartels M.J., Barton H.A., Boogaard P.J., Lipscomb J., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W., Hays S.M. Guidelines for the communication of biomonitoring equivalents: report from the biomonitoring equivalents expert workshop. Regul. Toxicol. Pharmacol. 2008, 51:S16-S26.
28. Levy C.W., Roujeinikova A., Sedelnikova S., Baker P.J., Stuitje A.R., Slabas A.R., Rice D.W., Rafferty J.B. Molecular basis of triclosan activity. Nature 1999, 398:383-384.
29. Mage D.T., Allen R.H., Gondy G., Smith W., Barr D.B., Needham L.L. Estimating pesticide dose from urinary pesticide concentration data by creatinine correction in the Third National Health and Nutrition Examination Survey (NHANES-III). J. Expo. Anal. Environ. Epidemiol. 2004, 14:457-465.
30. McGinnis, D., 2008. Toxicological Profile of Triclosan in the Aquatic Environment - Derivation of a National Water Quality Criterion. Department of Marine and Environmental Systems, Florida Institute of Technology. http://www.dalemcginnis.com/docs/triclosan.pdf.
31. McMurry L.M., Oethinger M., Levy S.B. Overexpression of marA, soxS, or acrAB producesresistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol. Lett. 1998, 166:305-309.
32. Moss T., Howes D., Williams F.M. Percutaneous penetration and dermal metabolism of triclosan (2,4,4'-trichloro-2'-hydroxydiphenyl ether). Food Chem. Toxicol. 2000, 38:361-370.
33. National Industrial Chemicals Notification and Assessment Scheme (NICNAS), 2009. Australian Government, Department of Health and Ageing. Priority Existing Chemical Assessment Report No. 30, Triclosan, January (May 21th, 2009). http://www.nicnas.gov.au/Publications/CAR/PEC/PEC30/PEC_30_Full_Report_PDF.pdf.
34. Perencevich E.N., Wong M.T., Harris A.D. National and regional assessment of the antibacterial soap market: a step toward determining the impact of prevalent antibacterial soaps. Am. J. Infect. Control 2001, 29:281-283.
35. Perucca J., Bouby N., Valeix P., Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R700-R705.
36. Queckenberg C., Meins J., Wachall B., Doroshyenko O., Tomalik-Scharte D., Bastian B., Abdel-Tawab M., Fuhr U. Absorption, pharmacokinetics and safety of triclosan after dermal administration. Antimicrob. Agents Chemother. 2009, 54:570-572.
37. Remer T., Fonteyn N., Alexy U., Berkemeyer S. Longitudinal examination of 24-h urinary iodine excretion in schoolchildren as a sensitive, hydration status-independent research tool for studying iodine status. Am. J. Clin. Nutr. 2006, 83:639-646.
38. Remer T., Neubert A., Maser-Gluth C. Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research. Am. J. Clin. Nutr. 2002, 75:561-569.
39. Samuel B.U., Hearn B., Mack D., Wender P., Rothbard J., Kirisits M.J., Mui E., Wernimont S., Roberts C.W., Muench S.P., Rice D.W., Prigge S.T., Law A.B., McLeod R. Delivery of antimicrobials into parasites. Proc. Natl. Acad. Sci. USA 2003, 55:14281-14286.
40. Sandborgh-Englund G., Adolfsson-Erici M., Odham G., Ekstrand J. Pharmacokinetics of triclosan following oral ingestion in humans. J. Toxicol. Environ. Health A 2006, 69:1861-1873.
41. Sullivan A., Wretlind B., Nord C.E. Will triclosan in toothpaste select for resistant oral streptococci?. Clin. Microbiol. Infect. 2003, 9:306-309.
42. Surolia N., Ramachandra Rao S.P., Surolia A. Paradigm shifts in malaria parasite biochemistry and anti-malarial chemotherapy. Bioessays 2001, 31:192-196.
43. USEPA, 2008a. Reregistration Eligibility Decision for Triclosan, (May 21th, 2009). http://www.epa.gov/oppsrrd1/REDs/2340red.pdf.
44. USEPA (United States Environmental Protection Agency), 2008b. Child-specific Exposure Factors Handbook. National Center for Environmental Assessment, Office of Research and Development. EPA/600/R-06/096F.
45. Wang L.Q., Falany C.N., James M.O. Triclosan as a substrate and inhibitor of 3'-phosphoadenosine-5'-phosphosulfatesulfotransferase and UDP-glucuronosyl transferase in human liver fractions. Drug Metab. Dispos. 2004, 32:1162-1169.
46. Wolff M.S., Teitelbaum S.L., Windham G., Pinney S.M., Britton J.A., Chelimo C., Godbold J., Biro F., Kushi L.H., Pfeiffer C.M., Calafta A.M. Pilot study of urinary biomarkers of phytoestrogens, phthalates, and phenols in girls. Environ. Health Perspect. 2007, 115:116-117.
47. World Health Organization (WHO), 1999. International Programme on Chemical Safety: Assessing Human Health Risks of Chemicals: Principles for the Assessment of Risk to Human Health from Exposure to Chemicals. Environmental Health Criteria 210, World Health Organisation, Geneva.
48. Yazdankhah S.P., Scheie A.A., Høiby E.A., Lunestad B.T., Heir E., Fotland T.Ø., Naterstad K., Kruse H. Triclosan and antimicrobial resistance in bacteria: an overview. Microb. Drug Resist. 2006, 12:83-90.
49. Zorrilla L.M., Gibson E.K., Jeffay S.C., Crofton K.M., Setzer W.R., Cooper R.L., Stoker T.E. The effects of triclosan on puberty and thyroid hormones in male Wistar rats. Toxicol. Sci. 2009, 107:56-64.